LYHER® Urine Marijuana (THC) Test Kit (Strip), LYHER® Urine Marijuana (THC) Test Kit (Cassette)

K232604 · Hangzhou Laihe Biotech Co., Ltd. · LDJ · Jan 10, 2024 · Clinical Toxicology

Device Facts

• Record ID: K232604
• Device Name: LYHER® Urine Marijuana (THC) Test Kit (Strip), LYHER® Urine Marijuana (THC) Test Kit (Cassette)
• Applicant: Hangzhou Laihe Biotech Co., Ltd.
• Product Code: LDJ · Clinical Toxicology
• Decision Date: Jan 10, 2024
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.3870
• Device Class: Class 2

Indications for Use

The LYHER® Urine Multi-Drug Test Kit (Cup), LYHER® Urine Multi- Drug Test Kit (Cassette), and LYHER® Urine Multi-Drug Test Kit (Dipcard) are rapid lateral flow immunoassays for the qualitative detection of d-Amphetamine, d-Methamphetamine, Benzoylecgonine, Morphine, Phencyclidine and THC-COOH in human urine. The test cut-off concentrations and the compounds the tests are calibrated to are as follows: Test Calibrator Cut-off (ng/mL) Amphetamine (AMP) d-Amphetamine 1000 Cocaine (COC) Benzoylecgonine 300 Marijuana (THC) 11-nor-Δ9-THC-9-COOH 50 Methamphetamine (MET) d-Methamphetamine 1000 Opiates(OPI) Morphine 2000 Phencyclidine (PCP) Phencyclidine 25 The single or multi-test panels can consist of the above listed analytes in any combination, up to a maximum of 6 analytes. The drug screen tests are intended for prescription use only. The tests provide only a preliminary result. A more specific alternative chemical method should be used in order to obtain a confirmed presumptive result. Gas Chromatography/Mass Spectrometry (GC/MS), Liquid Chromatography / Mass Spectrometry (LC/MS) and their tandem mass-spectrometer versions are the preferred confirmatory methods. Careful consideration and judgment should be applied to any drugs of abuse screen test result, particularly when evaluating preliminary positive results.

Device Story

Rapid lateral flow immunochromatographic assays for qualitative detection of drugs of abuse in human urine. Device formats include cup, cassette, and dipcard. Principle of operation: competitive binding between drug-protein conjugates on membrane strips and drug metabolites in urine sample for limited antibody binding sites. Colloidal gold particles coated with mouse monoclonal antibodies and rabbit IgG used as tracers. If drug present below cutoff, burgundy T-line appears; if above, no T-line develops. C-line serves as internal control. Used in clinical settings by healthcare professionals. Provides preliminary results requiring confirmation via GC/MS or LC/MS. Benefits include rapid screening for drugs of abuse to inform clinical decision-making.

Clinical Evidence

Bench testing only. Precision/reproducibility evaluated across three labs using 50 replicates per concentration level (0-100 ng/mL). Analytical specificity/cross-reactivity tested against structural analogues and common interfering substances. Method comparison performed against LC/MS using 80+ urine samples per device type, showing high concordance. No clinical studies performed.

Technological Characteristics

Lateral flow immunochromatographic assay; competitive binding principle. Membrane strips coated with drug-protein conjugates; conjugate pad contains colloidal gold-labeled monoclonal antibodies. Form factors: cup, cassette, dipcard. Storage: 2-30°C. No electronic components or software algorithms.

Indications for Use

Indicated for qualitative detection of d-Amphetamine, d-Methamphetamine, Benzoylecgonine, Morphine, Phencyclidine, and THC-COOH in human urine for prescription use. Intended for professional use to obtain preliminary drug screening results.

Regulatory Classification

Identification

A cannabinoid test system is a device intended to measure any of the cannabinoids, hallucinogenic compounds endogenous to marihuana, in serum, plasma, saliva, and urine. Cannabinoid compounds include delta-9-tetrahydrocannabinol, cannabidiol, cannabinol, and cannabichromene. Measurements obtained by this device are used in the diagnosis and treatment of cannabinoid use or abuse and in monitoring levels of cannabinoids during clinical investigational use.

Special Controls

*Classification.* Class II (special controls). A cannabinoid test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

Predicate Devices

• BIOEASY Marijuana Test Dip Card 40 (K192515)
• BIOEASY Marijuana Test Dip Card 20 (K192515)
• BIOEASY Marijuana Test Strip 40 (K192515)
• BIOEASY Marijuana Test Strip 20 (K192515)

Submission Summary (Full Text)

{0}

FDA U.S. FOOD & DRUG ADMINISTRATION

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

ASSAY ONLY

## I Background Information:

A 510(k) Number

K232604

B Applicant

Hangzhou Laihe Biotech Co., Ltd.

C Proprietary and Established Names

LYHER® Urine Marijuana (THC) Test Kit (Strip), LYHER® Urine Marijuana (THC) Test Kit (Cassette)

D Regulatory Information

| Product Code(s) | Classification | Regulation Section | Panel |
| --- | --- | --- | --- |
| LDJ | Class II | 21 CFR 862.3870 - Cannabinoid Test System | TX - Clinical Toxicology |

## II Submission/Device Overview:

A Purpose for Submission:

New device

B Measurand:

11-nor-Δ9-THC-9-COOH

C Type of Test:

Qualitative, lateral flow immunoassay

## III Intended Use/Indications for Use:

Food and Drug Administration

10903 New Hampshire Avenue

Silver Spring, MD 20993-0002

www.fda.gov

{1}

K232604 - Page 2 of 8

A Intended Use(s):

See Indications for Use below.

B Indication(s) for Use:

The LYHER® Urine Marijuana (THC) Test Kit (Strip) and LYHER® Urine Marijuana (THC) Test Kit (Cassette) are rapid lateral flow immunoassays for the qualitative detection of THC-COOH in human urine. The test cut-off concentrations and the compounds the tests are calibrated to are as follows:

| Test | Calibrator | Cut-off (ng/mL) |
| --- | --- | --- |
| Marijuana (THC) | 11-nor-Δ9-THC-9-COOH | 50 |

The drug screen tests are intended for prescription use only.

The tests provide only a preliminary result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical test result. Gas Chromatography/Mass Spectrometry (GC/MS), Liquid Chromatography/Mass Spectrometry (LC/MS) and their tandem mass-spectrometer versions are the preferred confirmatory methods. Careful consideration and judgment should be applied to any drugs of abuse screen test result, particularly when evaluating preliminary positive results.

C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only

D Special Instrument Requirements:

None

IV Device/System Characteristics:

A Device Description:

The LYHER® Urine Marijuana (THC) Test Kit (Strip) and LYHER® Urine Marijuana (THC) Test Kit (Cassette) are immunochromatographic assays that use a lateral flow system for the qualitative detection of THC-COOH in human urine. The LYHER® Urine Marijuana (THC) Test Kit (Cassette) device consists of a cassette device, dropper, and package insert. The LYHER® Urine Marijuana (THC) Test Kit (Strip) device consists of a test strips and package insert.

B Principle of Operation:

The Urine Marijuana (THC) Test Kit is an immunoassay based on the principle of competitive binding. The metabolite of Marijuana (11-nor-Δ9-THC-9-COOH) which may be present in the

{2}

urine specimen compete against its respective drug conjugate for binding sites on their specific antibody.

During testing, a urine specimen migrates upward by capillary action. A drug, if present in the urine specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test line region of the specific drug strip. The presence of drug above the cut-off concentration will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test line region.

A drug-positive urine specimen will not generate a colored line in the specific test line region of the strip because of drug competition, while a drug-negative urine specimen will generate a line in the test line region because of the absence of drug competition.

To serve as a procedural control, a colored line will always appear at the control line region, indicating that proper volume of specimen has been added and membrane wicking has occurred.

V Substantial Equivalence Information:

A Predicate Device Name(s):

BIOEASY Marijuana Test Dip Card 40, BIOEASY Marijuana Test Dip Card 20, BIOEASY Marijuana Test Strip 40, BIOEASY Marijuana Test Strip 20

B Predicate 510(k) Number(s):

K192515

C Comparison with Predicate(s):

| Device & Predicate Device(s): | K232604 | K192515 |
| --- | --- | --- |
| Device Trade Name | LYHER® Urine Marijuana (THC) Test Kit (Strip) and LYHER® Urine Marijuana (THC) Test Kit (Cassette) | BIOEASY Marijuana Test Dip Card 40, BIOEASY Marijuana Test Dip Card 20, BIOEASY Marijuana Test Strip 40, BIOEASY Marijuana Test Strip 2 |
| General Device Characteristic Similarities | | |
| Intended Use/Indications For Use | For the qualitative determination of Marijuana metabolites in human urine. | Same |
| Test Principle | Lateral flow immunochromatographic assay based on | Same |

K232604 - Page 3 of 8

{3}

K232604 - Page 4 of 8

VI Standards/Guidance Documents Referenced:

None referenced.

VII Performance Characteristics (if/when applicable):

A Analytical Performance:

1. Precision/Reproducibility:

Precision of the product was characterized at three different labs using 3 operators for strips or cassettes. The specimens were prepared for this study using drug-free urine specimens collected from volunteers. 11-nor-Δ9-THC-9-COOH was added to the drug-free urine to the following concentrations: 100 ng/ml (+100% cut off), 87.5 ng/ml (+75% cut off), 75 ng/ml (+50% cut off), 62.5 ng/ml (+25% cut off), 50 ng/ml (cut off), 37.5 ng/ml (-25% cut off), 25 ng/ml (-50% cut off), 12.5 ng/ml (-75% cut off), 0 ng/ml (-100% cut off). Each specimen was analyzed in 50 replicates (2 runs/day, 25 days) by each of the testing personnel at each lab by using three lots of the product according to the product labeling. The test results of the specimens at the concentrations at and below -25% of the cut off obtained by all the three personnel were all negative while the test results of the specimens at the concentration at and above +25% of the cut off value were all positive, see the representative results from one operator with strips below.

| Lot | -100% cut off | -75% cut off | -50% cut off | -25% cut off | Cut off | 25% cut off | 50% Cut off | 75% cut off | 100% cut off |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lot1:2303321 | 0+/50- | 0+/50- | 0+/50- | 0+/50- | 39+/11- | 50+/0- | 50+/0- | 50+/0- | 50+/0- |
| Lot2:2303322 | 0+/50- | 0+/50- | 0+/50- | 0+/50- | 40+/10- | 50+/0- | 50+/0- | 50+/0- | 50+/0- |
| Lot3:2303323 | 0+/50- | 0+/50- | 0+/50- | 0+/50- | 39+/11- | 50+/0- | 50+/0- | 50+/0- | 50+/0- |

2. Linearity:

Not applicable

3. Analytical Specificity/Interference:

a. Cross-reactivity

{4}

11-nor-Δ9-THC-9-COOH and structural analogues of 11-nor-Δ9-THC-9-COOH were spiked into negative urine. These urine specimens were tested by three different batches of the strips and cassettes according to the product labeling and each concentration of specimen was tested for 20 replicates. The lowest concentration that caused a positive result for each compound are listed below. There were no differences observed for stripes and cassettes.

| Compound | Concentration (ng/mL) | %Cross Reactivity |
| --- | --- | --- |
| Cannabinol | 20000 | 0.25% |
| 11-nor- Δ 8-THC-9 COOH | 30 | 167% |
| 11-nor- Δ 9 -THC-9 COOH | 50 | 100% |
| Δ 8 -THC | 15000 | 0.33% |
| Δ 9 -THC | 15000 | 0.33% |
| (±)-11-Hydroxy-Δ9-THC | 5000 | 1% |
| Cannabidiol | 20000 | 0.25% |

## b. Interferences

The potential interference from compounds chemically dissimilar to target analyte, and known endogenous agents was also determined for the LYHER® Urine Marijuana (THC) Test Kit (Strip) and LYHER® Urine Marijuana (THC) Test Kit (Cassette). The potential interfering substances (the final concentration 100 µg/ml) were added at concentrations of 100 µg/ml to drug-free urine and target drugs urine with 11-nor-Δ9-THC-9-COOH concentrations at 25% below (37.5 ng/ml) and 25% above (62.5 ng/ml) cut-off levels. These urine samples were tested using three batches of each device. Compounds that showed no interference at a concentration of 100 µg/mL are summarized in the following tables. There were no differences observed for 3 different lots of devices (both strips and cassettes).

| Substance | Substance | Substance |
| --- | --- | --- |
| Acetaminophen | Erythromycin | Penicillin-G |
| Acetone | Ethanol | Pheniramine |
| Acetylsalicylic acid | Furosemide | Phenothiazine |
| Albumin | Gabapentin | Pregablin |
| Ampicillin | Glucose | Procaine |
| Ascorbic acid | Guaiacol
glyceryl ether | Propoxyphene |
| Aspartame | Hemoglobin | Quinidine |
| Atropine | Ibuprofen | Ranitidine |
| Benzocaine | Isoproterenol | Riboflavin |
| Bilirubin | Isoproterenol | Sertraline |
| Caffeine | Ketamine | Sodium chloride |
| Chloroquine | Lidocaine | Sulindac |
| Chlorpheniramine | l-Phenylephrine | Theophylline |
| Creatine | Methadone | Tyramine |
| Dexbrompheniramine | Methylephedrine | β-Phenylethylamine |
| Dextromethorphan | Naproxen | Phencyclidine(PCP) |
| Dimenhydrinate | Niacinamide | Cocaine |
| Dimethylaminoantipyrine | Nicotine | Morphine |
| Diphenhydramine | Norephedrine | Methylamphetamine |

K232604 - Page 5 of 8

{5}

K232604 - Page 6 of 8

| Dopamine | Oxalic acid | MDMA |
| --- | --- | --- |
| EDDP | Oxycodone | Amphetamine |
| Ephedrine | Pantoprazole | |

c. Urine pH and specific gravity

To evaluate the potential effect of variances of urine specific gravity on the assays, sodium chloride was added to urine specimens containing target drugs at -/+25% of the cut off concentrations to achieve specific gravity results of 1.003, 1.006, 1.0125, 1.019, 1.021, 1.025 and 1.032. Each solution was tested on 3 lots of the stripes and cassettes. The specimens were tested in 10 replicates.

To evaluate the potential effect of variances of urine pH on the assays, 0.1mol/L HCl or 0.1mol/l NaOH was added to urine specimens containing target drugs at -/+25% of the cut off concentrations to achieve pH 3, 4, 5, 6, 7, 8, 9. Each solution was tested on 3 lots of the candidate product. The specimens were tested in 10 replicates.

The results demonstrated that pH levels of 3 to 9 and specific gravity levels of 1.006 to 1.032 do not affect any cassette and strip results.

4. Assay Reportable Range:

Not applicable.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

The device is traceable commercially available standards.

6. Detection Limit:

Not applicable.

7. Assay Cut-Off:

See the precision study in section VII A1 above.

B Comparison Studies:

1. Method Comparison with LC/MS:

Method comparison studies for the LYHER® Urine Marijuana (THC) Test Kit (Strip) and LYHER® Urine Marijuana (THC) Test Kit (Cassette) were performed in-house with three operators for each device. Operators ran at least 80 (40 negative and 40 positive) unaltered urine samples. The samples were blind labeled and compared to LC/MS results. The results are presented in the tables below:

| Cassettes | Test result | Negative urine | <-50% cut off | -50% cut off~cut off | Cut off~+50%cut off | >+50%cut off |
| --- | --- | --- | --- | --- | --- | --- |

{6}

| Operator 1 | Negative | 44 | 4 | 17 | 1 | 0 |
| --- | --- | --- | --- | --- | --- | --- |
| | Positive | 0 | 0 | 0 | 24 | 15 |
| Operator 2 | Negative | 44 | 4 | 16 | 2 | 0 |
| | Positive | 0 | 0 | 1 | 23 | 15 |
| Operator 3 | Negative | 44 | 4 | 17 | 0 | 0 |
| | Positive | 0 | 0 | 0 | 25 | 15 |

Discordant Results of THC Cassettes

| Operator | Specimen No. | LC/MS results | Results of Lyher kit |
| --- | --- | --- | --- |
| Operator 1 | 202301036 | 50.5 | Neg |
| Operator 2 | 202301060 | 52.3 | Neg |
| Operator 2 | 202301069 | 49.6 | Pos |
| Operator 2 | 202301651 | 51.1 | Neg |
| Strips | Test result | Negative urine | <-50% cut off | -50% cut off~cut off | Cut off~+50%cut off | >+50%cut off |
| --- | --- | --- | --- | --- | --- | --- |
| Operator 1 | Negative | 44 | 4 | 17 | 2 | 0 |
| | Positive | 0 | 0 | 0 | 23 | 15 |
| Operator 2 | Negative | 44 | 4 | 17 | 0 | 0 |
| | Positive | 0 | 0 | 0 | 25 | 15 |
| Operator 3 | Negative | 44 | 4 | 16 | 2 | 0 |
| | Positive | 0 | 0 | 1 | 23 | 15 |

Discordant Results of THC Strips

| Operator | Specimen No. | LC/MS results | Results of Lyher kit |
| --- | --- | --- | --- |
| Operator 3 | 202301036 | 50.5 | Neg |
| Operator 3 | 202301060 | 52.3 | Neg |
| Operator 1 | 202301099 | 52.3 | Neg |
| Operator 1 | 202301651 | 51.1 | Neg |

2. Matrix Comparison:

Not applicable

C Clinical Studies:

1. Clinical Sensitivity:

Not applicable

2. Clinical Specificity:

Not applicable

K232604 - Page 7 of 8

{7}

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):

Not applicable

D. Clinical Cut-Off:

Not applicable.

E. Expected Values/Reference Range:

Not applicable.

VIII. Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

IX. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

K232604 - Page 8 of 8